Our missionTo publish independent, practical, patient-orientated, evidence-based content on medicines for healthcare professionals.
Our visionTo improve the health of patients through the safe and effective use of medicines.
Expert authors – We commission subject experts to review and reflect on the latest drugs and therapeutics issues facing healthcare professionals Quality curated content – All content is edited to present information in a coherent and concise format, providing quick access to key messages, the impact on clinical practice and information relevant to patients Sponsorship and advertising free – As a founder member of The International Society of Drug Bulletins we are completely independent of commercial and government sponsorship. We do not take advertising in any form Monthly Podcasts – Editors discuss key points from articles in the latest issue of DTB and topical issues relating to medicines
Rigorous and transparent editorial process – Articles are peer reviewed externally by subject experts and the DTB editorial team Totally independent – We are committed to ensuring that our authors and editorial team have no financial or advisory (paid or unpaid) relationships with the pharmaceutical or healthcare industry* Published by BMJ – As one of the UK’s first evidence-based medical publications, DTB is now owned by BMJ, a global healthcare knowledge provider with a vision for a healthier world, bmj.com Discussion and debate – We welcome responses, questions and comments to our content through our rapid responses
Reviews – concise and pragmatic overviews on the safe and effective use of medicines and other treatments including key areas of controversy or uncertainty Editorials – written by guest authors and the DTB editorial team who specialise on the chosen topic DTB commentaries – overviews of a clinical trial, systematic review or observational study. The series is coordinated by Dr Teck Khong from the DTB editorial team DTB forum – initiatives or contentious issues relating to the use of medicines or other therapeutic interventions
DTB select – succinct, contextualised summaries on recent healthcare topics and publications, with brief comments on the strengths, anomalies, ambiguities, errors or omissions DTB drug reviews – brief summaries of the benefits and harms of medicines recently launched in the UK Case reports – in conjunction with BMJ Case Reports we feature republished cases that involve recently marketed drugs for which there is limited knowledge of adverse effects and cases that highlight unusual reactions to drugs that have been marketed for several years
DTB would like to address and curate content on the issues that matter to you:
Do you have ideas for articles that you would like to see published in DTB? Do you have a question on therapeutics that you would like DTB to tackle? Do you want more information about a particular drug? Please contact Deputy Editor David Phizackerley with your ideas.
DTB is a founding member of the International Society of Drug Bulletins (ISDB) and a founding member of the Committee on Publication Ethics (COPE).
* within the last three calendar years. Author disclosure forms are published with all articles as supplementary files and include: Association with commercial entities that provided support for the submitted manuscript; Association with commercial entities that could be viewed as having an interest in the general area of the submitted manuscript; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events; Support for attending meetings and/or travel; Non-financial associations that may be relevant to the submitted manuscript.